1.Aristolactam I against IL-6 (IC50 = 52 ± 8 μM) and TNFα (IC50 =116.8 ± 83.25 μM), respectively.
2.Aristolactam showed higher nephrotoxicity than aristolochic acid, which might be attributable to the differences in their inhibition of AQP1.
3.Aristolactam I possesses strong in vitro antimycobacterial activity against Mycobacterium tuberculosis H37Rv with MIC values ranging between 12.5 and 25 μg/mL.
->>Products covered by valid patents are not offered or supplied for commercial use.
->>Products currently covered by valid US Patents are offered for laboratory R&D use in accordance with 35 USC 271(e)+A13(1).
->>Any patent infringement and resulting liability is solely at buyer's risk.
->>Our products are only raw materials for drugs or industry, can't be used for human or animals directly.